Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 339

1.

Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma.

Hus M, Grzasko N, Szostek M, Pluta A, Helbig G, Woszczyk D, Adamczyk-Cioch M, Jawniak D, Legiec W, Morawska M, Kozinska J, Waciński P, Dmoszynska A.

Ann Hematol. 2011 Oct;90(10):1161-6. doi: 10.1007/s00277-011-1276-2. Epub 2011 Jun 23.

2.

Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan.

Wu SY, Yeh YM, Chen YP, Su WC, Chen TY.

Ann Hematol. 2012 Nov;91(11):1773-8. doi: 10.1007/s00277-012-1506-2. Epub 2012 Jun 17.

PMID:
22706703
3.

Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.

Steurer M, Spizzo G, Mitterer M, Gastl G.

Onkologie. 2004 Apr;27(2):150-4.

PMID:
15138347
4.

Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.

Barlogie B.

Semin Hematol. 2003 Oct;40(4 Suppl 4):33-8. Review.

PMID:
15015894
5.

Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.

Lee SS, Suh C, Kim BS, Chung J, Joo YD, Ryoo HM, Do YR, Jin JY, Kang HJ, Lee GW, Lee MH, Shim H, Kim K, Yoon SS, Bang SM, Kim HY, Lee JJ, Park J, Lee DS, Lee JH; Korean Multiple Myeloma Working Party.

Ann Hematol. 2010 Sep;89(9):905-12. doi: 10.1007/s00277-010-0943-z. Epub 2010 Mar 27.

PMID:
20349060
6.

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.

Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM.

Blood. 2008 Dec 1;112(12):4445-51. doi: 10.1182/blood-2008-02-141614. Epub 2008 Sep 17.

7.

A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.

Ahn JS, Yang DH, Jung SH, Park HC, Moon JH, Sohn SK, Bae SY, Kim YK, Kim HJ, Lee JJ; Korean Multiple Myeloma Working Party (KMMWP).

Ann Hematol. 2012 Jul;91(7):1023-30. doi: 10.1007/s00277-012-1420-7.

PMID:
22314843
8.

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J, Granell M, Besalduch J, Palomera L, González Y, Etxebeste MA, Díaz-Mediavilla J, Hernández MT, de Arriba F, Gutiérrez NC, Martín-Ramos ML, Cibeira MT, Mateos MV, Martínez J, Alegre A, Lahuerta JJ, San Miguel J, Bladé J; Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group.

Blood. 2012 Aug 23;120(8):1589-96. Epub 2012 Jul 12.

9.

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.

Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, Crippa C, Boccadoro M, Perrone G, Falcone A, Nozzoli C, Zambello R, Masini L, Furlan A, Brioli A, Derudas D, Ballanti S, Dessanti ML, De Stefano V, Carella AM, Marcatti M, Nozza A, Ferrara F, Callea V, Califano C, Pezzi A, Baraldi A, Grasso M, Musto P, Palumbo A; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Italian Myeloma Network.

Blood. 2012 Jul 5;120(1):9-19. doi: 10.1182/blood-2012-02-408898. Epub 2012 Apr 12.

10.

Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant.

Palumbo A, Falco P, Ambrosini MT, Petrucci MT, Musto P, Caravita T, Pregno P, Bertola A, Cavallo F, Ciccone G, Boccadoro M.

Eur J Haematol. 2005 Nov;75(5):391-5.

PMID:
16191088
11.

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC.

Blood. 2002 Nov 1;100(9):3063-7.

12.

Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.

Delforge M, Michiels A, Doyen C, Kentos A, Van Droogenbroeck J, Offner F, Bries G, Demuynck H, Vekemans MC, Meuleman N, Mineur PO, Ravoet C, Depryck B, Van de Velde A, Pierre P, Wu KL, Schots R.

Acta Clin Belg. 2011 Sep-Oct;66(5):371-5.

PMID:
22145272
13.

Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.

Palumbo A, Avonto I, Bruno B, Ambrosini MT, Bringhen S, Cavallo F, Falco P, Boccadoro M.

Eur J Haematol. 2006 Apr;76(4):273-7.

PMID:
16519697
14.

Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.

Offidani M, Bringhen S, Corvatta L, Falco P, Marconi M, Avonto I, Piersantelli MN, Polloni C, Boccadoro M, Leoni P, Palumbo A.

Eur J Haematol. 2007 Apr;78(4):297-302. Epub 2007 Feb 5.

PMID:
17286608
15.

Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.

Richardson P.

Semin Hematol. 2005 Oct;42(4 Suppl 4):S9-15. Review.

PMID:
16344100
16.

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.

Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N, Eleftherakis-Papaiakovou E, Tsionos K, Croucher P, Dimopoulos MA.

Leukemia. 2008 Dec;22(12):2247-56. doi: 10.1038/leu.2008.235. Epub 2008 Sep 4.

PMID:
18769451
17.

[Thalidomide with or without dexamethasone for refractory multiple myeloma].

Boulin M, Blanchet F, Isambert N, Solary E, Solier S, Collin B, Pernot C, Durnet-Archeray MJ.

Therapie. 2002 Nov-Dec;57(6):524-9. French.

PMID:
12666259
18.

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.

Kropff M, Baylon HG, Hillengass J, Robak T, Hajek R, Liebisch P, Goranov S, Hulin C, Bladé J, Caravita T, Avet-Loiseau H, Moehler TM, Pattou C, Lucy L, Kueenburg E, Glasmacher A, Zerbib R, Facon T.

Haematologica. 2012 May;97(5):784-91. doi: 10.3324/haematol.2011.044271. Epub 2011 Dec 1.

19.

Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma.

Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K.

Semin Hematol. 2003 Oct;40(4 Suppl 4):3-7. Review.

PMID:
15015890
20.

Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.

Ahmad I, Islam T, Chanan-Khan A, Hahn T, Wentling D, Becker JL, McCarthy PL Jr, Alam AR.

Bone Marrow Transplant. 2002 Apr;29(7):577-80.

Items per page

Supplemental Content

Write to the Help Desk